1 / 17

CJ Allegra, G Yothers, MJ O ’ Connell, MS Roh, RW Beart,

Neoadjuvant Therapy For Rectal Cancer: Mature Results From NSABP Protocol R-04 A Collaborative National NCI Protocol Conducted by NSABP, NCCTG, ECOG, CALGB, and SWOG. CJ Allegra, G Yothers, MJ O ’ Connell, MS Roh, RW Beart, NJ Petrelli, S Lopa, S Sharif, and N Wolmark. Disclosures.

kiri
Download Presentation

CJ Allegra, G Yothers, MJ O ’ Connell, MS Roh, RW Beart,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Neoadjuvant Therapy For Rectal Cancer: Mature Results From NSABP Protocol R-04A Collaborative National NCI Protocol Conducted by NSABP, NCCTG, ECOG, CALGB, and SWOG CJ Allegra, G Yothers, MJ O’Connell, MS Roh, RW Beart, NJ Petrelli, S Lopa, S Sharif, and N Wolmark

  2. Disclosures • I have no relevant conflicts of interest to disclose

  3. Goals of NSABP R-04 • Designed at the start of the millennium to address the questions: • Can the oral fluoropyrimidine, capecitabine be substituted for the standard of care in the curative setting of Stage II & III rectal cancer namely, CIV 5-FU, during neoadjuvant RT? • CIV 5-FU became the SoC based on a US cooperative group study (O’Connell et al; NEJM August, 1994) showing superiority over bolus administrations of 5-FU • Capecitabine was shown to be non-inferior to 5-FU in the palliative & adjuvant colon settings and does not require a central venous catheter or infusion pump • Small retrospective studies support similar outcomes with 5-FU and capecitabine in the rectal neoadjuvant setting • Can the addition of oxaliplatin enhance the activity of fluoropyrimidine sensitized RT? • Oxaliplatin was shown to have radiation sensitizing properties in preclinical models • Oxaliplatin was shown to enhance the activity of 5-FU in the palliative and adjuvant colon settings

  4. NSABP R-04 • July, 2004 ACTIVATION • 2-arm study comparing 5-FU and Cape • October, 2005 AMENDMENT • Added oxaliplatin • 2 x 2 factorial design • 5-FU and Cape reduced from 7 days/wk to 5 days/wk during RT • August, 2010CLOSED • 1,608 accrued patients; 1595 (99.2%) Eligible

  5. NSABP R-04 Rectal AdenoCa < 12 cm from anal verge STRATIFICATION Gender; Clinical Stage II/III; Intent for Type of Surgery (sphincter saving v. APR) Group 1 5-FU (CIV 225mg/m2 5d/wk) + RT (46Gy over 5 wks + boost) Group 2 5-FU (CIV 225mg/m2 5d/wk) + Oxaliplatin 50 mg/m2/wk X 5 + RT RANDOMIZATION Group 3 Capecitabine 825 mg/m2 PO BID + RT Group 4 Capecitabine 825 mg/m2 PO BID + Oxaliplatin 50 mg/m2/wk X 5 + RT

  6. NSABP R-04– Primary Endpoint – • Local-regional control with 3 years minimum follow-up • Time from randomization to first L-R failure • Inoperable patients or those with positive margins are considered L-R failures at the time of surgery • Patients without documented clinical CR who do not undergo surgery will be considered a L-R failure at the time they should have had surgery • “Local” – Anastomotic and pelvis • “Regional” – Pelvic or retroperitoneal LNs at or below L5

  7. NSABP R-04 –Secondary Endpoints – • Rate of pathologic CR • Number of pts undergoing sphincter-saving surgery • Disease free and overall survival • Quality of Life • Toxicity • Correlating genetic patterns and specific tissue biomarkers with response and prognosis

  8. NSABP R-04Statistical Design • Comparison of cape and 5-FU • Comparable if 0.86 < HazRatio < 1.17 • Roughly corresponds to 3yr L-R rate of +/- 2% • Superiority for the addition of oxaliplatin to fluoropyrimidines • >80% power for HazRatio = 0.59 • Roughly corresponds to 4% increase in L-R 3yr rate

  9. Patient Demographics

  10. NSABP R-04 pCR Rates (%) P = 0.14 P = 0.42 * No significant fluoropyrimidine by oxaliplatin interaction

  11. 3 Year Overall & L-R Recurrences P = 0.98 P = 0.70 P = 0.52 P = 0.22 * No significant fluoropyrimidine by oxaliplatin interaction

  12. 5 year Outcomes (%) P = 0.70 P = 0.34 P = 0.61 P = 0.38 * No significant fluoropyrimidine by oxaliplatin interaction

  13. NSABP R-04 Primary Endpoint: Local-Regional Control 5-FU vs. Cape No Oxali vs. Oxali 100 100 80 80 60 60 5-FU 782 Pts, 95 L/R Recurrence No Oxali 641 Pts, 81 L/R Recurrence L/R Recurrence Free (%) L/R Recurrence Free (%) Cape 785 Pts, 97 L/R Recurrence Oxali 643 Pts, 76 L/R Recurrence 40 40 HR = 1.00, 95% CI (0.75-1.32) HR = 0.94, 95% CI (0.67-1.29) P = 0.98 P = 0.70 20 20 0 0 0 1 2 3 4 5 6 0 1 2 3 4 5 6 Years from Randomization Years from Randomization

  14. NSABP R-04 Overall Survival 5-FU vs. Cape No Oxali vs. Oxali 100 100 80 80 60 60 No Oxali 641 Pts, 116 deaths 5-FU 782 Pts, 141 deaths Alive (%) Alive (%) Cape 785 Pts, 138 deaths Oxali 643 Pts, 103 deaths 40 HR = 1.00, 95% CI (0.74-1.19) 40 HR = 0.94, 95% CI (0.68-1.16) P = 0.61 P = 0.38 20 20 0 0 0 1 2 3 4 5 6 0 1 2 3 4 5 6 Years from Randomization Years from Randomization

  15. Treatment Compliance • At least 80% of treatment completed per protocol • FU – 90% alone; 84% with Oxali • Cap – 97% alone; 96% with Oxali • Oxali – 69% with FU; 62% with Cap • RT – 96-98% depending on the arm

  16. NSABP R-04 Mortality & Adverse Events (%)

  17. NSABP R-04 Summary • Capecitabine with preop RT achieved rates similar to CIV 5-FU for: • L-R Failure – Primary Endpoint • pCR • DFS • OS • Oxaliplatin did not improve outcomes but added significant toxicity (diarrhea) and is therefore not indicated in combination with RT in the preop rectal setting • Establishes capecitabine as a standard of care in the preop rectal setting • NSABP R-04 supports pCR & neoadjuvant rectal cancer (NAR) score as surrogates for overall survival (Yothers G ASCO GI, 2014; Abst #384) • Fully annotated tissue samples available for molecular studies

More Related